When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry

When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry

Bibliographic Details
Main Authors:	Eftychios Siniorakis, Spyridon Arvanitakis, Maximilianos Elkouris, Efstratios Katsianos, Panayotis Pelonis, Antonia Tertipi
Format:	Article
Language:	English
Published:	Elsevier 2020-03-01
Series:	Revista Portuguesa de Cardiologia
Online Access:	http://www.sciencedirect.com/science/article/pii/S087025512030127X

Similar Items

Response to the Letter to the Editor “When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry”
by: Cândida Fonseca, et al.
Published: (2020-03-01)

Cardiac glycosides and COVID-19: would it be a promising therapeutic approach?
by: EFTYCHIOS SINIORAKIS, et al.
Published: (2020-10-01)

COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure
by: Eftychios Siniorakis, et al.
Published: (2020-06-01)

Angiotensin Receptor–Neprilysin Inhibition (Sacubitril/Valsartan) Reduces Structural Arterial Stiffness in Middle‐Aged Mice
by: Isabel N. Schellinger, et al.
Published: (2024-02-01)

Angiotensin II Receptor–Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats
by: Takunori Seki, et al.
Published: (2017-10-01)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
by: Josep Lupón, et al.
Published: (2021-01-01)

Effect of sacubitril/valsartan on brain natriuretic peptide level and prognosis of acute cerebral infarction
by: Xiaozhu Shen, et al.
Published: (2023-01-01)

Effect of sacubitril/valsartan on brain natriuretic peptide level and prognosis of acute cerebral infarction.
by: Xiaozhu Shen, et al.
Published: (2023-01-01)

Sacubitril/Valsartan for heart failure
by: Wenqin Dai, MM, et al.
Published: (2022-06-01)

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
by: Javad Habibi, et al.
Published: (2019-03-01)

Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
by: Akihiro Nakamura, et al.
Published: (2023-01-01)

Sacubitril/valsartan: A practical guide
by: Cândida Fonseca, et al.
Published: (2019-05-01)

Sacubitril/Valsartan inhibits M1 type macrophages polarization in acute myocarditis by targeting C-type natriuretic peptide
by: Changhu Liu, et al.
Published: (2024-05-01)

Initiation, treatment response evaluation, and safety monitoring of angiotensin receptor/neprilysin inhibitors (Sacubitril/Valsartan) in the management of heart failure in India: An expert group recommendations
by: Uday M Jadhav, et al.
Published: (2023-01-01)

Use of sacubitril/valsartan early after CABG
by: Madina Nurzhanova, et al.
Published: (2024-01-01)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
by: Margherita Ilaria Gioia, et al.
Published: (2022-06-01)

Angioedema with concomitant use of sacubitril/valsartan and enalapril
by: Logamoorthy Ramamoorthy, et al.
Published: (2023-01-01)

Sacubitril/valsartan in real-life clinical practice
by: Yüksel Çavuşoğlu
Published: (2021-07-01)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
by: Nor Hidayah Mustafa, et al.
Published: (2022-08-01)

Myocardial damage after prolonged accidental hypothermia: a case report
by: Siniorakis Eftychios, et al.
Published: (2009-07-01)

The PARAGON Heart Failure trial – ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction
by: Sverre E. Kjeldsen, et al.
Published: (2019-07-01)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
by: Ying Ding, et al.
Published: (2023-12-01)

Potential of valsartan+sacubitril therapy in hypertensive heart disease
by: A. G. Ovchinnikov, et al.
Published: (2021-08-01)

Sacubitril/Valsartan Ameliorates Crizotinib-Induced Cardiotoxicity in Mice
by: Lijun Cheng, et al.
Published: (2023-07-01)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
by: Luís Beck-da-Silva, et al.

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
by: Ana Martín‐Garcia, et al.
Published: (2020-04-01)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
by: Giuseppe Vergaro, et al.
Published: (2021-02-01)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018-08-01)

Roles of Natriuretic Peptides and the Significance of Neprilysin in Cardiovascular Diseases
by: Hitoshi Nakagawa, et al.
Published: (2022-07-01)

Angiotensin receptor-neprilysin inhibition by sacubitril/valsartan attenuates doxorubicin-induced cardiotoxicity in a pretreatment mice model by interfering with oxidative stress, inflammation, and Caspase 3 apoptotic pathway
by: Ferhat Dindaş, et al.
Published: (2021-11-01)

Sacubitril/Valsartan in the Treatment of Resistant Hypertension: Raising Star or Illusion?
by: Marijana Tadic, et al.
Published: (2022-05-01)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
by: Yu Xu, et al.
Published: (2023-05-01)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
by: Cong Zhao, et al.
Published: (2022-11-01)

Pathogenetic justification of sacubitril / valsartan use in respiratory-cardial comorbidity
by: T. V. Ashcheulova, et al.
Published: (2023-01-01)

The effects of sacubitril/valsartan and ramipril on the male fertility in hypertensive rats
by: Duygun Altıntaş Aykan, et al.
Published: (2020-10-01)

Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
by: Alex Heyse, et al.
Published: (2019-12-01)

Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view
by: Borja Quiroga, et al.
Published: (2019-11-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

Switching to sacubitril/valsartan or adding aldosterone antagonist: which first?
by: Carlos Escobar, et al.
Published: (2019-12-01)

Sacubitril/valsartan alleviates myocardial fibrosis in diabetic cardiomyopathy rats
by: Jiao Ai, et al.
Published: (2021-09-01)